Myriad Genetics MYGN RoW — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's row — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Myriad Genetics's row — revenue?
- Myriad Genetics (MYGN) reported row — revenue of $13.4M in Q1 2026.
- How has Myriad Genetics's row — revenue changed year-over-year?
- Myriad Genetics's row — revenue decreased by 6.3% year-over-year, from $14.3M to $13.4M.
- What is the long-term trend for Myriad Genetics's row — revenue?
- Over 4 years (2021 to 2025), Myriad Genetics's row — revenue has grown at a -10.2% compound annual growth rate (CAGR), from $86.9M to $56.5M.
- What does row — revenue mean?
- This metric represents the total revenue generated from the company's operations outside of its primary domestic market. It serves as a key indicator of the firm's international market penetration and the scalability of its diagnostic testing services in global territories. Tracking this figure helps investors assess geographic diversification and the impact of international regulatory or competitive environments on overall top-line performance.